Clinical Trial Update: Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessed how Symbicort Forte Turbohaler particles deposit in the lungs and the acute effects in COPD patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort Forte Turbohaler (budesonide/formoterol)

Snippet

Sponsor: University Hospital, Antwerp | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED